Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen expects generic biologics

Executive Summary

"Generic biologics will happen and I think we'll see them in Europe first," Amgen CEO Kevin Sharer told investors Feb. 25. The exec noted that generic biologics are "profoundly different" from conventional generic drugs, citing the need to conduct clinical trials and the larger required investment in manufacturing facilities as examples. Sharer expects that Amgen's Epogen (epoetin alfa) in Europe would be the company's first product to face generic competition; however, the CEO said, "from our patent lives here in the U.S. and for the newer products in Europe, it's a long way out for us"...

You may also be interested in...

BIO Likes EU Model For Follow-On Biologics; Standards Are “Appropriate”

The European Union approach to follow-on biologic products sets an "appropriate" standard, the Biotechnology Industry Organization said

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts